Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2020-08-28 AGM Information
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Hauptversammlung 2020, Fresenius
AGM Information Classification · 99% confidence The document text is titled 'Hauptversammlung – Fresenius SE & Co. KGaA' (Annual General Meeting - Fresenius SE & Co. KGaA) and contains several bullet points and sections typical of a presentation given at a shareholder meeting, such as 'Herzlich willkommen!', performance highlights ('Robust wirtschaftliche Entwicklung trotz Pandemie'), dividend proposals ('27. Dividendenerhöhung in Folge vorgeschlagen'), and strategic updates. The term 'Hauptversammlung' directly translates to Annual General Meeting (AGM). Therefore, this document is classified as AGM Information.
2020-08-28 German
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section labeled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Dr. Gerd Krick), their position, the nature of the transaction ('Acquisition'), the financial instrument (Share), and the price/volume details of the transaction on a specific date (2020-08-05). This content directly matches the definition for Director's Dealing.
2020-08-05 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'DGAP-DD: Fresenius SE & Co. KGaA english' and contains the header 'Directors’ Dealings'. Section 4 details 'Details of the transaction(s)' involving an acquisition of shares by a 'person discharging managerial responsibilities' (Rachel Empey, Member of the managing body). This content directly matches the definition for Director's Dealing reports.
2020-08-03 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' as of July 31, 2020. It details a 'Type of capital measure' related to a 'Conditional capital increase' and provides the 'New total number of voting rights'. This content directly relates to changes in the company's share structure and voting power, which falls under Capital/Financing Update (CAP) or potentially a specific regulatory filing. However, given the focus on the total number of voting rights resulting from a capital measure, 'Capital/Financing Update' (CAP) is the most precise fit among the provided definitions, as it covers capital structure changes. It is not a general AGM result (DVA) or a director's dealing (DIRS).
2020-07-31 English
Half-yearly financial report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-Year Financial Report' for Fresenius Group for the first half of 2020. It contains comprehensive financial statements, including consolidated statements of income, cash flows, and financial position, as well as detailed management discussion and analysis of business segments. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2020
2020-07-31 English
Conference Call Q2 Results 2020, Fresenius
Investor Presentation Classification · 99% confidence The document text explicitly states '# Conference Call – Q2/20 Results' and contains detailed operational updates, segment performance tables, and financial highlights (Sales, EBIT, Net Income, Cash Flow) for the second quarter (Q2/20). The structure, including a Safe Harbor statement, management commentary, and segment breakdowns, is characteristic of an earnings call presentation or transcript. Since the text provided is the content of the call/presentation, the most appropriate classification is 'Call Transcript' (CT), as it represents the spoken/presented material related to the earnings announcement, rather than just the initial press release (ER) or the full annual report (10-K).
2020-07-30 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.